PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Walter, S.* ; Weinschenk, T.* ; Stenzl, A.* ; Zdrojowy, R.* ; Pluzanska, A.* ; Szczylik, C.* ; Staehler, M.* ; Brugger, W.* ; Dietrich, P.Y.* ; Mendrzyk, R.* ; Hilf, N.* ; Schoor, O.* ; Fritsche, J.* ; Mahr, A.* ; Maurer, D.* ; Vass, V.* ; Trautwein, C.* ; Lewandrowski, P.* ; Flohr, C.* ; Pohla, H. ; Stanczak, J.J.* ; Bronte, V.* ; Mandruzzato, S.* ; Biedermann, T.* ; Pawelec, G.* ; Derhovanessian, E.* ; Yamagishi, H.* ; Miki, T.* ; Hongo, F.* ; Takaha, N.* ; Hirakawa, K.* ; Tanaka, H.* ; Stevanovic, S.* ; Frisch, J.* ; Mayer-Mokler, A.* ; Kirner, A.* ; Rammensee, H.-G.* ; Reinhardt, C.* ; Singh-Jasuja, H.*

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

J. Nat. Med. 18, 1254-1261 (2012)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02(+) subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)(+) regulatory T (T(reg)) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of T(reg) cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
22.462
5.270
334
650
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Language english
Publication Year 2012
HGF-reported in Year 2013
ISSN (print) / ISBN 1340-3443
e-ISSN 1861-0293
Journal Journal of natural medicines
Quellenangaben Volume: 18, Issue: 8, Pages: 1254-1261 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Tokyo [u.a.]
Reviewing status Peer reviewed
Institute(s) Institute of Molecular Immunology (IMI)
POF-Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s) Immune Response and Infection
PSP Element(s) G-501700-001
PubMed ID 22842478
DOI 10.1038/nm.2883
Scopus ID 84864662070
Erfassungsdatum 2013-08-05
[➜Report correction]